Satranidazole


CAS No. : 56302-13-7

56302-13-7
Price and Availability of CAS No. : 56302-13-7
Size Price Stock
1g $1510 Get quote
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-119475
M.Wt: 289.27
Formula: C8H11N5O5S
Purity: >98 %
Solubility:
Introduction of 56302-13-7 :

Satranidazole is an orally effective insecticide and antimicrobial agent with high electron affinity. Satranidazole forms reduced nitro intermediates, which interact with DNA, causing helix instability, strand breakage and release of thymidine derivatives. Satranidazole exhibits antitrichomonal activity against Trichomonas vaginalis and Trichomonas foetus, and antiamoebic activity in rodent models of hepatic amoebiasis and caecal amoebiasis. Satranidazole inhibits the replication of bacteriophage φX174 DNA. Satranidazole can be used in research related to caecal amoebiasis, trichomoniasis and anaerobic bacterial infections[1][2]. In Vitro:Satranidazole induces extensive DNA damage in *E. coli* at compound-to-nucleotide ratios of 0.5:1 and 1:1, including helix destabilization, strand breakage, thymidine release, and reduced viscosity[1].
Satranidazole inactivates bacteriophage φX174 DNA at a compound-to-nucleotide ratio of 1:1, with a T37 of 2.41 h and an R37 of 3.85, indicating the presence of biologically relevant DNA damage[1].
Satranidazole (8 h) potently inhibits reference strains and clinical isolates of anaerobic bacteria in vitro, with an MIC90 of 0.25 mg/L against 50 clinical isolates, and its MIC values are lower than those of the control drugs in most tested strains[2]. In Vivo:Satranidazole exhibits superior activity to Metronidazole (HY-B0318) in a mouse model of caecal amebiasis[1].
Satranidazole demonstrates amoebicidal activity in a golden hamster model of liver, caecal, or combined Entamoeba histolytica infection[1].
Satranidazole exhibits superior activity to Metronidazole in a mouse model of subcutaneous Trichomonas vaginalis or Trichomonas foetus infection[1].
Satranidazole (2-32 mg/kg; p.o.; 3 doses) exhibits potent protective activity against fatal Fusobacterium necrophorum septicaemia in mice, with an ED50 of 2.10 mg/kg[2].
Satranidazole (10-100 mg/kg; p.o.; twice) demonstrates dose-dependent bactericidal activity against subcutaneous Bacteroides fragilis abscesses in mice, achieving a 3-log cfu reduction at 10 mg/kg and complete sterilization at 100 mg/kg[2].

Your information is safe with us.